It also determined that CK1α facilitates AML by inhibiting p53 downstream of MDM2-mediated autophagy and apoptosis, suggesting that targeting CK1α presents a therapeutic opportunity for AML treatment. Here, TP53 is linked to acute myeloid leukemia.